Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1218-1222

  Co, Mary Dawn T ^a,b   Cruz, John ^a,b   Takeda, Akira ^a,b   Ennis, Francis A ^a,b   Terajima, Masanori ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibody; Complement dependent lytic; Hemagglutination inhibition; Influenza virus; Microneutralization; Vaccine

Indexed keywords

COMPLEMENT DEPENDENT LYTIC ANTIBODY; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLUENZA A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LYSIS; NORMAL HUMAN; OUTCOME ASSESSMENT; STATISTICAL ANALYSIS; VACCINATION; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 84867017625     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21025     Document Type: Article

References (26)

1. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115:63-73; PMID:15088777.
2. Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des Devel Ther 2009; 3:7-16; PMID:19920917.
3. Verbonitz MW, Ennis FA, Hicks JT, Albrecht P. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J Exp Med 1978; 147:265-70; PMID:627837; http://dx.doi.org/10.1084/jem.147.1.265.
4. Co MD, Orphin L, Cruz J, Pazoles P, Rothman AL, Ennis FA, et al. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 2008; 26:1990-8; PMID:18339461; http://dx.doi.org/10.1016/j.vaccine.2008.02.024.
5. Szretter KJ, Balish AL, Katz JM. Influenza: propagation, quantification, and storage. Curr Protoc Microbiol 2006; Chapter 15:Unit 15G 1.
6. Quinnan GV, Ennis FA, Tuazon CU, Wells MA, Butchko GM, Armstrong R, et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980; 30:362-9; PMID:7439982.
7. Reading PC, Hartley CA, Ezekowitz RA, Anders EM. A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells. Biochem Biophys Res Commun 1995; 217:1128-36; PMID:8554567; http://dx.doi.org/ 10.1006/bbrc.1995.2886.
8. Papenburg J, Baz M, Hamelin ME, Rheaume C, Carbonneau J, Ouakki M, et al. Evaluation of serological diagnostic methods for the 2009 pandemic influenza A (H1N1) virus. Clin Vaccine Immunol; 18:520-2.
9. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262:5-25; PMID:17598812; http://dx.doi.org/10.1111/j.1365- 2796.2007.01819.x.
10. Hicks JT, Ennis FA, Kim E, Verbonitz M. The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol 1978; 121:1437-45; PMID:701803.
11. Hicks JT, Klutch MJ, Albrecht P, Frank MM. Analysis of complement-dependent antibody-mediated lysis of target cells acutely infected with measles. J Immunol 1976; 117:208-15; PMID:819582.
12. Qu Z, Liang X, Liu Y, Du J, Liu S, Sun W. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. Mol Immunol 2009; 47:283-9; PMID:19804910; http://dx.doi.org/10.1016/j.molimm. 2009.09.022.
13. Sissons JG, Cooper NR, Oldstone MB. Alternative complement pathway-mediated lysis of measles virus infected cells: induction by IgG antibody bound to individual viral glycoproteins and comparative efficacy of F(ab')2 and Fab' fragments. J Immunol 1979; 123:2144-9; PMID:489977.
14. Patrick Sissons JG, Schreiber RD, Perrin LH, Cooper NR, Müller-Eberhard HJ, Oldstone MB. Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody. J Exp Med 1979; 150:445-54; PMID:479760; http://dx.doi.org/10.1084/jem.150.3.445.
15. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, et al. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011; 85:13463-7; PMID:21994454; http://dx.doi.org/10.1128/JVI.05193-11.
16. Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006; 352:418-26; PMID:16777168; http://dx.doi.org/10.1016/ j.virol.2006.05.008.
17. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2008; 2:243-9; PMID:19453401; http://dx.doi.org/ 10.1111/j.1750-2659.2008.00059.x.
18. Palese P. Influenza: old and new threats. Nat Med 2004; 10(Suppl):S82-7; PMID:15577936; http://dx.doi.org/10.1038/nm1141.
19. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. The Journal of experimental medicine; 208:181-93.
20. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71; PMID:18449194; http://dx.doi.org/10.1038/ nature06890.
21. Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985; 82:1785-9; PMID:3872457; http://dx.doi.org/10.1073/pnas.82.6.1785.
22. Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 2010; 107:12658-63; PMID:20615945; http://dx.doi.org/10.1073/pnas.0911806107.
23. Palese P, Shaw M. Orthomyxoviridae: The Viruses and Their Replication. In: David M. Knipe PMH, ed. Fields' virology Philadelphia: Lippincott Williams & Wilkins 2007:1655,722-723.
24. Gardner EM, Bernstein ED, Dran S, Munk G, Gross P, Abrutyn E, et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. Vaccine 2001; 19:4610-7; PMID:11535308; http://dx.doi.org/10.1016/S0264-410X(01)00246-8.
25. Hirota Y, Kaji M, Ide S, Goto S, Oka T. The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Vaccine 1996; 14:1597-602; PMID:9032887; http://dx.doi.org/10.1016/S0264- 410X(96)00153-3.
26. Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 2004; 103:125-32; PMID:15163500; http://dx.doi.org/10.1016/j.virusres.2004.02.024.